Research article · 14 Apr 2026
Research articlePublished 13 Jun 2022
SARS-CoV-2 Rapid Antigen Test: Laboratory Validation of the Performance of POCT Antigen Test Kits of COVID-19
1Department of Nursing Sciences, Zhejiang Gongshang University, Hangzhou, China; 2Department of Nursing Sciences, Wenzhou Medical University, Wenzhou, China
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
With the advent of deadly SARS-CoV-2, public health organizations and researchers emphasized the timely detection and identification of the virus to limit the spread. Different tests were designed to detect coronaviruses for timely and rapid identification, including Polymerase Chain Reaction (PCR) that detects the organism's genetic material. This research aims to validate the performance of Point-of-care testingantigen test kits of COVID-19, including the Lateral Flow Test (LFT) and the lateral Flow Immunofluorescent Assay (FIA) is intended for qualitative detection of SARS-CoV-2 nucleocapsid antigen. This evaluation involved six different rapid test kits, including Fia Test ATFNCG21040001, All Test ATNCP21060014, All Test ATNCP21060015, All Test ATNCP21060012, Abbott Panbio Cov-19 Ag Rapid Test, and Siemens Rapid COVID-19 Antigen Test. In addition, another study also compare the SARS-CoV-2 Antigen Rapid Test (COVID-19 Antigen Rapid Test) (Swab) manufactured by Hangzhou All Test Biotech Co., Ltd.; 2019-nCoV Antigen Test, manufactured by Guangzhou Wondfo Biotech Co., Ltd.; SARS-CoV-2 Rapid Antigen Test, manufactured by Roche, the molecular SARS-COV-2 assay (nucleic acid extraction using the automatic system Versant, followed by RT-PCR using the FDT SARS-CoV-2 kit) manufactured by Siemens from Germany that meets EU CE standards, to evaluate the clinical effectiveness of candidate kit. The Nasopharyngeal Swab (NPS) samples were collected and analysed by RT-PCR method. The specificity of all rapid test kits was greater than 99.9%, whereas the sensitivity ranged from 91 to >99%, which is also significant. The finding suggests the rapid antigen test can be used as an effective tool in controlling COVID-19 promptly. Moreover, these tests can also be conducted by a layman or at home for primary identification of COVID-19, which would limit the transmission of disease.
Keywords
Subjects
Infectious DiseasesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Infectious Diseases & Therapy.
Research article · 5 May 2025
The Ultimate Cure for the COVID Syndemic
Mini review · 29 Apr 2025
COVID-19 Systematic Mini-Review as of April 2025
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Infectious Diseases & Therapy
- SubjectInfectious Diseases
- BylineArticles whose byline prints “Zhang Lie”
- BylineArticles whose byline prints “Yang Feng”
- BylineArticles whose byline prints “Zhu Junzhe”